Larry K. Kociolek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Larry K. Kociolek has a total of 423 co-authors. Here are the top co-authors by number of shared publications:
- Egon Anderson Ozer
Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
10 shared publications Sameer J. Patel
Pediatric Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA
9 shared publicationsStanford T. Shulman
Department of Pediatrics, Northwestern University Feinberg School of Medicine
9 shared publicationsDale N. Gerding
Department of Medicine, Loyola University Chicago Stritch School of Medicine, 2160 S. 1st Ave, Maywood, IL, 60153, USA; Department of Medicine, Edward Hines, Jr. Veterans Administration Hospital, 5000 5th Ave, Hines, IL, 60141, USA
8 shared publicationsAmi B. Patel
Department of Pediatrics, Northwestern University Feinberg School of Medicine
6 shared publications- Dale N. Gerding
Research Service, Edward Hines Jr Veterans Affairs Hospital , Hines, Illinois
6 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by American Society for Microbiology in mSphere
- Vol. 11 (9)
A novel integrative and conjugative element in Streptococcus pyogenes carries a cfr -like gene associated with linezolid resistance in other species
Treatment of severe invasive Streptococcus pyogenes infections has historically relied on β-lactam antibiotics with adjunctive clindamycin. Rising rates of lincosamide resistance have led to adoption of linezolid as an alternative adjunctive therapy. This report describes a clinical S. pyogenes isolate carrying a multi-drug resistance gene, cfr (C), known to confer the phenicol, lincosamide, oxazolidinone, pleuromutilin, and streptogramin A (PhLOPS A ) resistance phenotype in other bacterial species. Strain GAS-390756 is a pharyngeal isolate collected from a child with pharyngitis in the United States. Whole-genome sequence analysis demonstrated that the isolate belonged to emm type 89 and carried an integrative and conjugative element with erm (B) and cfr (C) cargo genes (ICE Spy 390756). Antimicrobial susceptibility testing demonstrated the isolate was resistant to erythromycin and clindamycin but susceptible to linezolid, consistent with the activity of erm (B) but not cfr (C). Comparative analysis of cfr (C)’s genomic context suggested that the promoter sequence may have been lost during ICE Spy 390756’s acquisition of the gene. While GAS-390756 remains susceptible to linezolid, the expansion of cfr (C)’s host range into S. pyogenes and its presence on a novel mobile element are concerning. In light of known expression mechanisms for other silent antimicrobial resistance genes, this observation carries epidemiologic and public health importance. IMPORTANCE: Treatment of severe invasive Streptococcus pyogenes infection has traditionally relied on the adjunctive use of clindamycin with β-lactam antibiotic therapy. However, rising rates of clindamycin non-susceptibility have led clinicians to adopt linezolid as an alternative therapy. We identified S. pyogenes isolated from a child with pharyngitis that carried the cfr (C) gene. This gene causes resistance to multiple antibiotics, including clindamycin and linezolid, in other bacterial species. At the time of this study, we found no other instances of the cfr (C) gene carried by S. pyogenes in either published reports or the public genome sequence database. While this isolate remained sensitive to linezolid, the expanded host range of cfr (C) found in a novel potentially mobile genomic element may herald the eventual emergence of broader antibiotic resistance in S. pyogenes .
- 29 September 2026
- Published by American Society for Microbiology in mSphere
- Vol. 11 (9)
Open AccessA novel integrative and conjugative element in Streptococcus pyogenes carries a cfr -like gene associated with linezolid resistance in other species
Treatment of severe invasive Streptococcus pyogenes infections has historically relied on β-lactam antibiotics with adjunctive clindamycin. Rising rates of lincosamide resistance have led to adoption of linezolid as an alternative adjunctive therapy. This report describes a clinical S. pyogenes isolate carrying a multi-drug resistance gene, cfr (C), known to confer the phenicol, lincosamide, oxazolidinone, pleuromutilin, and streptogramin A (PhLOPS A ) resistance phenotype in other bacterial species. Strain GAS-390756 is a pharyngeal isolate collected from a child with pharyngitis in the United States. Whole-genome sequence analysis demonstrated that the isolate belonged to emm type 89 and carried an integrative and conjugative element with erm (B) and cfr (C) cargo genes (ICE Spy 390756). Antimicrobial susceptibility testing demonstrated the isolate was resistant to erythromycin and clindamycin but susceptible to linezolid, consistent with the activity of erm (B) but not cfr (C). Comparative analysis of cfr (C)’s genomic context suggested that the promoter sequence may have been lost during ICE Spy 390756’s acquisition of the gene. While GAS-390756 remains susceptible to linezolid, the expansion of cfr (C)’s host range into S. pyogenes and its presence on a novel mobile element are concerning. In light of known expression mechanisms for other silent antimicrobial resistance genes, this observation carries epidemiologic and public health importance. IMPORTANCE: Treatment of severe invasive Streptococcus pyogenes infection has traditionally relied on the adjunctive use of clindamycin with β-lactam antibiotic therapy. However, rising rates of clindamycin non-susceptibility have led clinicians to adopt linezolid as an alternative therapy. We identified S. pyogenes isolated from a child with pharyngitis that carried the cfr (C) gene. This gene causes resistance to multiple antibiotics, including clindamycin and linezolid, in other bacterial species. At the time of this study, we found no other instances of the cfr (C) gene carried by S. pyogenes in either published reports or the public genome sequence database. While this isolate remained sensitive to linezolid, the expanded host range of cfr (C) found in a novel potentially mobile genomic element may herald the eventual emergence of broader antibiotic resistance in S. pyogenes .
- Open Access
- 1 July 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (7) , e0035426
Identification of Streptococcus pyogenes isolates with reduced beta-lactam susceptibility in a cohort of children with pharyngitis
We investigated sequences of the penicillin-binding protein 2x (PBP2x) among 902 Streptococcus pyogenes isolates from children with pharyngitis. Twenty-five pharyngeal isolates carried variants associated with reduced β-lactam susceptibility. Penicillin and ampicillin susceptibility testing confirmed reduced susceptibility among PBP2x variant isolates relative to those with the wild-type sequence.
- 1 July 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (7) , e0035426
Open AccessIdentification of Streptococcus pyogenes isolates with reduced beta-lactam susceptibility in a cohort of children with pharyngitis
We investigated sequences of the penicillin-binding protein 2x (PBP2x) among 902 Streptococcus pyogenes isolates from children with pharyngitis. Twenty-five pharyngeal isolates carried variants associated with reduced β-lactam susceptibility. Penicillin and ampicillin susceptibility testing confirmed reduced susceptibility among PBP2x variant isolates relative to those with the wild-type sequence.
- Open Access
- 26 May 2026
- Published by Elsevier in The Lancet Microbe
- p. 101429
Improving prediction of future Mycoplasma pneumoniae epidemics using data-driven transmission models
- 26 May 2026
- Published by Elsevier in The Lancet Microbe
- p. 101429
Open AccessImproving prediction of future Mycoplasma pneumoniae epidemics using data-driven transmission models
- Open Access
- 25 March 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1)
Molecular epidemiology and clinical differentiation between Clostridioides difficile infection and colonization across three chicago medical centers
In a retrospective cohort study at three Chicago academic medical centers, 22/81 (27.2%) patients with a clinically adjudicated positive C. difficile test result were colonized. Recent antibiotic usage predicted true infection (adjusted odds ratio: 4.38 for infection). Restriction endonuclease analysis(REA) group Y (29.3%) replaced BI (9.3%) as the dominant strain.
- 25 March 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1)
Open AccessMolecular epidemiology and clinical differentiation between Clostridioides difficile infection and colonization across three chicago medical centers
In a retrospective cohort study at three Chicago academic medical centers, 22/81 (27.2%) patients with a clinically adjudicated positive C. difficile test result were colonized. Recent antibiotic usage predicted true infection (adjusted odds ratio: 4.38 for infection). Restriction endonuclease analysis(REA) group Y (29.3%) replaced BI (9.3%) as the dominant strain.
- 7 August 2025
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 39 (4) , 709-725
Clostridioides difficile in Children
- 7 August 2025
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 39 (4) , 709-725
Clostridioides difficile in Children
- Open Access
- 23 July 2025
- Published by American Society for Microbiology in Applied and Environmental Microbiology
- Vol. 91 (7) , e0096425
Phenotypic analysis of various Clostridioides difficile ribotypes reveals consistency among core processes
Clostridioides difficile infections (CDI) cause almost 300,000 hospitalizations per year, of which ~15%–30% are the result of recurring infections. The prevalence and persistence of CDI in hospital settings have resulted in an extensive collection of C. difficile clinical isolates and their classification, typically by ribotype. While much of the current literature focuses on one or two prominent epidemic ribotypes (e.g., RT027), recent years have seen several other ribotypes dominate the clinical landscape (e.g., RT106 and RT078). Some ribotypes are associated with severe disease and/or increased recurrence rates, but why certain ribotypes are more prominent or harmful than others remains unknown. Because C. difficile has a large, open pan-genome, this observed relationship between ribotype and clinical outcome could be a result of the genetic diversity of C. difficile . Thus, we hypothesize that the core biological processes of C. difficile are conserved across ribotypes/clades. We tested this hypothesis by observing the growth kinetics, sporulation, germination, production of toxin A and toxin B, bile acid sensitivity, bile salt hydrolase activity, and surface motility of 15 strains belonging to various ribotypes spanning each known C. difficile clade. In viewing these phenotypes across each strain, we see that core phenotypes (growth, germination, sporulation, and resistance to bile salt toxicity) are remarkably consistent across clades/ribotypes. This suggests that variations observed in the clinical setting may be due to unidentified factors in the accessory genome or due to unknown host factors. IMPORTANCE: Clostridioides difficile infections impact thousands of individuals every year, many of whom experience recurring infections. Clinical studies have reported an unexplained correlation between some clades/ribotypes of C. difficile and disease severity/recurrence. Here, we demonstrate that C. difficile strains across major clades/ribotypes are consistent in their core phenotypes. This suggests that such phenotypes are not responsible for variations in disease severity/recurrence and are ideal targets for the development of therapeutics meant to treat C. difficile -related infections.
- 23 July 2025
- Published by American Society for Microbiology in Applied and Environmental Microbiology
- Vol. 91 (7) , e0096425
Open AccessPhenotypic analysis of various Clostridioides difficile ribotypes reveals consistency among core processes
Clostridioides difficile infections (CDI) cause almost 300,000 hospitalizations per year, of which ~15%–30% are the result of recurring infections. The prevalence and persistence of CDI in hospital settings have resulted in an extensive collection of C. difficile clinical isolates and their classification, typically by ribotype. While much of the current literature focuses on one or two prominent epidemic ribotypes (e.g., RT027), recent years have seen several other ribotypes dominate the clinical landscape (e.g., RT106 and RT078). Some ribotypes are associated with severe disease and/or increased recurrence rates, but why certain ribotypes are more prominent or harmful than others remains unknown. Because C. difficile has a large, open pan-genome, this observed relationship between ribotype and clinical outcome could be a result of the genetic diversity of C. difficile . Thus, we hypothesize that the core biological processes of C. difficile are conserved across ribotypes/clades. We tested this hypothesis by observing the growth kinetics, sporulation, germination, production of toxin A and toxin B, bile acid sensitivity, bile salt hydrolase activity, and surface motility of 15 strains belonging to various ribotypes spanning each known C. difficile clade. In viewing these phenotypes across each strain, we see that core phenotypes (growth, germination, sporulation, and resistance to bile salt toxicity) are remarkably consistent across clades/ribotypes. This suggests that variations observed in the clinical setting may be due to unidentified factors in the accessory genome or due to unknown host factors. IMPORTANCE: Clostridioides difficile infections impact thousands of individuals every year, many of whom experience recurring infections. Clinical studies have reported an unexplained correlation between some clades/ribotypes of C. difficile and disease severity/recurrence. Here, we demonstrate that C. difficile strains across major clades/ribotypes are consistent in their core phenotypes. This suggests that such phenotypes are not responsible for variations in disease severity/recurrence and are ideal targets for the development of therapeutics meant to treat C. difficile -related infections.
- Open Access
- 21 April 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (4) , e70030
Bacteremia in Pediatric Solid Organ Transplant Recipients within 1 Year of Transplant
Background: Bacteremia is a major cause of morbidity and mortality in immunocompromised children, yet there are limited data in children who have undergone solid organ transplantation (SOT). Methods: We retrospectively reviewed bloodstream infections (BSI) in 581 recipients of heart, liver, or kidney transplants over a 14‐year period. Results: Overall 1‐year incidence in this population was 8.4%, and was highest in recipients of liver transplants compared to heart or kidney. Younger age, transplantation earlier in the time period studied, need for repeat surgery within 30 days of transplant, and prior diagnosis of diabetes or tumor were associated with an increased risk of BSI. Most BSI occurred within 90 days of transplant, and most were associated with central venous lines. Coagulase‐negative staphylococci and enteric commensals were commonly isolated. Multiple BSI within the year after transplant were uncommon. Although overall mortality was not increased in patients with BSI compared to those without, patients with BSI had more total hospitalizations and more days spent in the hospital in the year following SOT. Conclusion: In a large pediatric SOT population, overall BSI rates were significant but decreased over time. Identifying factors which contribute to BSI after SOT may direct interventions that can impact inpatient care requirements for these patients. image
- 21 April 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (4) , e70030
Open AccessBacteremia in Pediatric Solid Organ Transplant Recipients within 1 Year of Transplant
Background: Bacteremia is a major cause of morbidity and mortality in immunocompromised children, yet there are limited data in children who have undergone solid organ transplantation (SOT). Methods: We retrospectively reviewed bloodstream infections (BSI) in 581 recipients of heart, liver, or kidney transplants over a 14‐year period. Results: Overall 1‐year incidence in this population was 8.4%, and was highest in recipients of liver transplants compared to heart or kidney. Younger age, transplantation earlier in the time period studied, need for repeat surgery within 30 days of transplant, and prior diagnosis of diabetes or tumor were associated with an increased risk of BSI. Most BSI occurred within 90 days of transplant, and most were associated with central venous lines. Coagulase‐negative staphylococci and enteric commensals were commonly isolated. Multiple BSI within the year after transplant were uncommon. Although overall mortality was not increased in patients with BSI compared to those without, patients with BSI had more total hospitalizations and more days spent in the hospital in the year following SOT. Conclusion: In a large pediatric SOT population, overall BSI rates were significant but decreased over time. Identifying factors which contribute to BSI after SOT may direct interventions that can impact inpatient care requirements for these patients. image
- Open Access
Phenotypic analysis of various Clostridioides difficile ribotypes reveals consistency among core processes
Clostridioides difficile infections (CDI) cause almost 300,000 hospitalizations per year of which ∼15-30% are the result of recurring infections. The prevalence and persistence of CDI in hospital settings has resulted in an extensive collection of C. difficile clinical isolates and their classification, typically by ribotype. While much of the current literature focuses on one or two prominent ribotypes ( e.g ., RT027), recent years have seen several other ribotypes dominate the clinical landscape ( e.g. , RT106 and RT078). Some ribotypes are associated with severe disease and / or increased recurrence rates, but why are certain ribotypes more prominent or harmful than others remains unknown. Because C. difficile has a large, open pan-genome, this observed relationship between ribotype and clinical outcome could be a result of the genetic diversity of C. difficile . Thus, we hypothesize that core biological processes of C. difficile are conserved across ribotypes / clades. We tested this hypothesis by observing the growth kinetics, sporulation, germination, bile acid sensitivity, bile salt hydrolase activity, and surface motility of fifteen strains belonging to various ribotypes spanning each known C. difficile clade. In viewing these phenotypes across each strain, we see that core phenotypes (growth, germination, sporulation, and resistance to bile salt toxicity) are remarkably consistent across clades / ribotypes. This suggests that variations observed in the clinical setting may be due to unidentified factors in the accessory genome or due to unknown host-factors. Importance: C. difficile infections impact thousands of individuals every year many of whom experience recurring infections. Clinical studies have reported an unexplained correlation between some clades / ribotypes of C. difficile and disease severity / recurrence. Here, we demonstrate that C. difficile strains across the major clades / ribotypes are consistent in their core phenotypes. This suggests that such phenotypes are not responsible for variations in disease severity / recurrence and are ideal targets for the development of therapeutics meant to treat C. difficile related infections.
Open AccessPhenotypic analysis of various Clostridioides difficile ribotypes reveals consistency among core processes
Clostridioides difficile infections (CDI) cause almost 300,000 hospitalizations per year of which ∼15-30% are the result of recurring infections. The prevalence and persistence of CDI in hospital settings has resulted in an extensive collection of C. difficile clinical isolates and their classification, typically by ribotype. While much of the current literature focuses on one or two prominent ribotypes ( e.g ., RT027), recent years have seen several other ribotypes dominate the clinical landscape ( e.g. , RT106 and RT078). Some ribotypes are associated with severe disease and / or increased recurrence rates, but why are certain ribotypes more prominent or harmful than others remains unknown. Because C. difficile has a large, open pan-genome, this observed relationship between ribotype and clinical outcome could be a result of the genetic diversity of C. difficile . Thus, we hypothesize that core biological processes of C. difficile are conserved across ribotypes / clades. We tested this hypothesis by observing the growth kinetics, sporulation, germination, bile acid sensitivity, bile salt hydrolase activity, and surface motility of fifteen strains belonging to various ribotypes spanning each known C. difficile clade. In viewing these phenotypes across each strain, we see that core phenotypes (growth, germination, sporulation, and resistance to bile salt toxicity) are remarkably consistent across clades / ribotypes. This suggests that variations observed in the clinical setting may be due to unidentified factors in the accessory genome or due to unknown host-factors. Importance: C. difficile infections impact thousands of individuals every year many of whom experience recurring infections. Clinical studies have reported an unexplained correlation between some clades / ribotypes of C. difficile and disease severity / recurrence. Here, we demonstrate that C. difficile strains across the major clades / ribotypes are consistent in their core phenotypes. This suggests that such phenotypes are not responsible for variations in disease severity / recurrence and are ideal targets for the development of therapeutics meant to treat C. difficile related infections.
- Open Access
- 14 November 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 46 (1) , 3-26
SHEA practice update: infection prevention and control (IPC) in residential facilities for pediatric patients and their families
In 2011, the Society for Healthcare Epidemiology of America (SHEA) and Ronald McDonald House Charities® (RMHC®) established a formal collaboration to develop the first IPC guideline. Both organizations agreed that RMH programs staff and other organizations operating similar programs would benefit from a standardized approach. In 2023, the collaboration was re-established to revise and update the original IPC guideline. This SHEA Practice Update on “Infection Prevention and Control (IPC) in Residential Facilities for Pediatric Patients and Their Families” addresses preventing transmission of infectious agents in “home away from home” residential settings, of which the Ronald McDonald Houses (RMHs) serve as a prototype.
- 14 November 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 46 (1) , 3-26
Open AccessSHEA practice update: infection prevention and control (IPC) in residential facilities for pediatric patients and their families
In 2011, the Society for Healthcare Epidemiology of America (SHEA) and Ronald McDonald House Charities® (RMHC®) established a formal collaboration to develop the first IPC guideline. Both organizations agreed that RMH programs staff and other organizations operating similar programs would benefit from a standardized approach. In 2023, the collaboration was re-established to revise and update the original IPC guideline. This SHEA Practice Update on “Infection Prevention and Control (IPC) in Residential Facilities for Pediatric Patients and Their Families” addresses preventing transmission of infectious agents in “home away from home” residential settings, of which the Ronald McDonald Houses (RMHs) serve as a prototype.
- 19 March 2024
- Published by Elsevier in Pediatric Clinics of North America
- Vol. 71 (3) , 431-454
Infection Prevention and Control Implications of Special Pathogens in Children
- 19 March 2024
- Published by Elsevier in Pediatric Clinics of North America
- Vol. 71 (3) , 431-454
Infection Prevention and Control Implications of Special Pathogens in Children